Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biovaxys Technology Corp (LMNGF)

Biovaxys Technology Corp (LMNGF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LMNGF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2602 +51.84%
on 02/04/21
0.6200 -36.27%
on 02/16/21
+0.1051 (+36.24%)
since 02/03/21
3-Month
0.0600 +558.50%
on 01/04/21
0.6200 -36.27%
on 02/16/21
+0.1826 (+85.93%)
since 12/03/20

Most Recent Stories

More News
As Additional COVID Variants Surface, Questions Arise to Effectiveness of Vaccines to Combat New Strains

, /PRNewswire/ -- The epic global race to solve the COVID-19 crisis has just gotten a be a more of a puzzle with the emergence of new variants. The existing vaccines have been based on research centered...

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
JNJ : 156.22 (-1.76%)
PFE : 34.39 (+2.63%)
MRNA : 131.22 (-10.62%)
INO : 9.56 (-4.59%)
BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

VANCOUVER, B.C. , March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ( "BioVaxys"), the world leader in haptenized protein vaccines for antiviral...

LMNGF : 0.3951 (-2.49%)
BIOV : N/A (unch)
BioVaxys Announces Appointment To Its Scientific Advisory Board

, /PRNewswire/ --BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic...

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
BioVaxys Announces Appointment To Its Scientific Advisory Board

BIOV : N/A (unch)
LMNGF : 0.3951 (-2.49%)
Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients

, /PRNewswire/ -- Ovarian cancer and its rising incidence rate is a growing concern worldwide and the rising incidence of ovarian cancer will be driving the ovarian cancer drugs market for years to come....

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
ONTX : 1.1500 (-4.17%)
ZIOP : 4.68 (-7.69%)
EVFM : 3.60 (-8.86%)
NKTR : 23.44 (-1.26%)
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF"BioVaxys" or "Company") announced today that it has signed a Term Sheet ("Term Sheet") with BioElpida S.A.S. ("BioElpida")...

LMNGF : 0.3951 (-2.49%)
BIOV.CN : 0.500 (-3.85%)
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production

SIGNIFICANT ADVANCEMENT TOWARDS LAUNCH OF PHASE I OVARIAN CANCER VACCINE TRIAL

BIOV : N/A (unch)
LMNGF : 0.3951 (-2.49%)
BioVaxys Announces Broadening Of Share Liquidity With DTCC Full Service Eligibility

LMNGF : 0.3951 (-2.49%)
BIOV : N/A (unch)
BioVaxys Announces Appointment of Corporate Advisor

BioVaxys Announces Appointment of Corporate Advisor

LMNGF : 0.3951 (-2.49%)

Key Turning Points

3rd Resistance Point 0.4985
2nd Resistance Point 0.4536
1st Resistance Point 0.4244
Last Price 0.3951
1st Support Level 0.3503
2nd Support Level 0.3054
3rd Support Level 0.2762

See More

52-Week High 0.6200
Fibonacci 61.8% 0.4007
Last Price 0.3951
Fibonacci 50% 0.3330
Fibonacci 38.2% 0.2653
52-Week Low 0.0460

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar